drugset / Trial / NCT04634253
A Study of LY3462817 in Participants With Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).
Timeline
- Start
- 2021-01-04
- Primary completion
- 2022-01-10
- Completion
- 2022-06-29
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs LY3462817 700 mg; p <0.001; LS Mean -1.09 (95% CI -1.73 to -0.46); Mixed Models Analysis NCT04634253 ↗
release “phase 2a study of peresolimab in rheumatoid arthritis (RA), in which peresolimab met the primary endpoint for efficacy” lilly.com ↗
Publications
- Tuttle J, Emery P, Nirula A. Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. Reply. N Engl J Med. 2023 Jul 27;389(4):378-379. doi: 10.1056/NEJMc2307020. No abstract available.
- Tuttle J, Drescher E, Simon-Campos JA, Emery P, Greenwald M, Kivitz A, Rha H, Yachi P, Kiley C, Nirula A. A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. N Engl J Med. 2023 May 18;388(20):1853-1862. doi: 10.1056/NEJMoa2209856.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peresolimab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Peresolimab | Monoclonal antibody | 700 mg | Intravenous |